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BACKGROUND፡ Anemia in patients with chronic kidney disease 
presents significant impacts on patients, the health-care system 
and financial resources. There is a significant variation in the 
primary studies on risk factors of anemia in this patient 
population across the globe.Therefore, this study aimed to identify 
the risk factors of anemia among chronic kidney disease patients 
at the global level. 
METHODS: PubMed, Scopus, African Journals Online, Web of 
Science and Google Scholar were searched and complemented by 
manual searches. A Funnel plot and Egger’s regression test were 
used to determine publication bias. DerSimonian and Laird 
random-effects modes were applied to estimate pooled effect sizes, 
odds ratios, and 95% confidence interval across studies. Analysis 
was performed using STATA™ Version 14 software. 
RESULT: A total of 28 studies with 24,008 study participants 
were included in this study. Female sex (AOR= 1.36; 95% CI 
1.11, 1.67), stage 5 CKD (AOR = 13.66; 95% CI: 5.19, 35.92), 
body mass index ≥ 30 kg/m2 (AOR = 0.51; 95% CI: 0.29, 0.91), 
comorbidities (AOR = 2.90; 95% CI: 1.68, 5.0), proteinuria 
3+(AOR = 3.57; 95% CI: 1.03, 12.93), hypocalcemia (AOR=3.61, 
95%CI: 1.56–8.36), and iron therapy (AOR: 0.59; 95% CI:0.31, 
0.98) were significantly associated with anemia of chronic kidney 
disease.  
CONCLUSION: Female sex, stage 5 CKD, body mass index ≥ 30 
kg/m2, comorbidity, and hypocalcemia were found to be 
significantly associated with anemia of chronic kidney disease. 
Therefore, situation-based interventions and country context-
specific preventive strategies should be developed to reduce the 
risk factors of anemia in patients with chronic renal failure. 
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Chronic Kidney Disease (CKD) is a rising global health problem, 
defined as kidney damage or glomerular filtration rate (GFR) of 
less than 60 mL/min/1.73 m2 for three months or more, irrespective 
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of the cause or evidence of kidney damage (1,2). 
Chronic kidney disease is emerging as a 
complex global health problem with a huge 
economic burden both on the affected family of 
patients and on the healthcare delivery system 
(3).  
Anemia is a serious complication of CKD 
and has significant adverse outcomes (4). When  
diseased kidney loses its ability to produce the 
erythropoietin essential to the production of 
hemoglobin, anemia is developed(5). Anemia 
with CKD is defined as a situation in which the 
concentration of hemoglobin (Hb) in the blood is 
below the mean Hb level (6). According to the 
Kidney Disease Improving Global Outcomes 
(KDIGO) Anemia Work Group, anaemia in 
CKD occurs when the Hb level is <13 g/dL for 
men and <12 g/dL for women (7). An estimated 
glomerular filtration rate (eGFR) of less than 60 
ml/min/1.73m2 is the best indicator for the 
investigation of anemia in CKD patients (8). 
Large differences have been reported on the 
magnitude of anemia in patients with CKD 
across studies. For instance, reports showed an 
anemia prevalence of 47.7% in the USA (9), 
39.36% in India (10), 97.8% in Brazil (11), 
51.5% in China (12), 79% in Cameroon (13), 
43.18% in South Africa (14), and 64.5% in 
Ethiopia (15). In addition, African Americans 
had a 3-fold increased likelihood of anemia 
compared with whites (16). 
Although the primary cause of anemia in 
patients with CKD is the inadequate production 
of erythropoietin by the kidneys to support 
erythropoiesis (17), there is also the result of a 
complex interplay between patient-specific 
attributes including diabetes with or without 
nephropathy (DN)(12), advanced CKD stages 
(12,14,18,19), nutritional deficiency (iron, folic 
acid, and vitamin B12) (20), diabetes mellitus 
(14), hematological disorders, not taking iron 
supplements, respiratory disorders (18), body 
mass index (BMI)<18.5 kg/m2, history of 
hemodialysis and rural residence (15), smoking, 
and reduced serum albumin (21). 
The potential adverse clinical outcomes of 
anemia in CKD patients include: cognitive 
impairment, angina, cardio-renal anemia 
syndrome (22), left ventricular hypertrophy 
(LVH) (23), higher healthcare costs and reduced 
quality of life (24,25), increased hospital 
admission rate (26), worsening CKD (27), 
accelerated progression of heart disease (4,27), 
and increased mortality (27,28). However, some 
studies have shown that early identification and 
prompt treatment of anemia through near 
normalization of hemoglobin and iron levels in 
CKD patients is associated with reduced renal 
disease progression, as well as improved energy, 
work capacity, health-related quality of life, 
cognitive function, and cardiac function (4,29). 
In addition, optimizing the Hbor hematocrit 
value before initiating dialysis may reduce 
mortality (25). Likewise, studies demonstrate 
that positive correlations between increases in 
hemoglobin levels and quality of life measures 
were reported (24,30,31). 
Different primary studies worldwide show 
the risk factors of anemia as a health issue on the 
continent. However, variation was observed 
among these studies. Therefore, this systematic 
review and meta-analysis aimed to identify risk 




Literature search strategy: Electronic 
databases such as PubMed, Google Scholar, 
African journals Online, Scopus, Web of 
Science, and Psyinfo were systematically 
searched. Grey literature such as surveillance 
reports, academic dissertations and conference 
abstracts was examined. In addition, the 
reference lists of the included articles were 
hand-searched to identify any potentially 
relevant articles.This search involved articles 
published from inception to February 13, 2020. 
The searches were restricted to full texts, free 
articles, human studies, and English language 
publications. Endnote X 8.1 reference manager 
software was used to collect and organize search 
outcomes and to remove duplicate articles.The 
search was conducted using the following terms 
and phrases: “anaemia”, “risk factors”, 
“associated factors”, “chronic kidney injury”, 
“chronic kidney disease”, “chronic renal 
insufficiency”, “global”, “international” and “list 
of continent”. Boolean operators such as “AND” 
and “OR” were used to combine search terms.  
 
Eligibility criteria: Studies were included in the 
meta-analysis if they fulfilled the following 
criteria: (1). all observational studies 
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investigating risk factors of anemia in patients 
with CKD, (2) articles published in peer-
reviewed journals or grey literature, and (3) 
articles published in English from inception to 
2020. Studies were excluded if: (1) they were 
not fully accessible, (2) they were duplicated 
citations, and (3) they possessed a poor quality 
score as per the stated criteria. 
 
Data extraction and quality assessment: Two 
independent investigators screened the titles and 
abstracts of all potential studies. Data were 
extracted from each of these studies using the 
standardized data extraction format prepared in a 
Microsoft™Excel worksheet by the three 
authors independently. For each included article, 
we extracted data regarding the name(s) of the 
author(s),year of publication, study area, study 
design, sample size, data collection year, 
sampling technique, diagnostic criteria used for 
anemia, reported prevalence with its 95% 
Confidence Interval (CI) and information 
regarding the associated factors.The quality of 
each included study was assessed using the 
Newcastle-Ottawa scale (NOS)(32). Studies 
were included in the analysis if they scored ≥5 
out of 10 points in three domains of ten modified 
NOS components for observational studies. Any 
disagreements at the time of data abstraction 
were resolved by discussion and consensus 
(Supplementary file 1). In addition, the risk of 
bias of selected articles was assessed using the 
risk of bias tool for prevalence studies developed 
by Hoy et al. Two authors carried out the risk of 
bias assessment of the included studies 
independently. 
 
Statistical analysis: To obtain risk factors for 
anemia in patients with CKD, a meta-analysis 
using the random-effects DerSimonian and Laird 
model was performed (33). Cochran’s Q chi-
square statistics and I2 statistical tests were 
conducted to assess the random variations 
between primary studies (34).To investigate the 
sources of heterogeneity, meta-regression and 
subgroup analyses were performed. Potential 
publication bias was assessed by visually 
inspecting funnel plots and objectively using the 
Egger bias test (35). Sensitivity analysis was 
used to see the effect of a single study on the 
overall effect estimation. Meta-analysis was 
performed using STATATM version 14 statistical 
softwarefor WindowsTM (36). 
 
Presentation and reporting of results: The 
results of this review were reported based on the 
Preferred Reporting Items for Systematic 
Review and Meta-Analysis statement (PRISMA) 
guidelines (37). The entire process of study 
screening, selection, and inclusion was described 
with the aid of a flow diagram. The results are 




Search results: The search strategy identified a 
total of 1,884 articles. Approximately 1,879 
studies were found from five international 
databases and the remaining 5 were identified 
through a manual search. The databases included 
PubMed (948), Scopus (156), Google Scholar 
(572), African Journals Online (171), and Web 
of Science (32). After excluding duplicate 
publications, 949 articles remained. 
Approximately 789 articles were excluded after 
reading the titles and abstracts based on the 
predefined eligibility criteria. Out of them, 160 
articles were included and screened for further 
assessment. Finally, 28 articles were included in 
the analysis. 
Baseline characteristics of the included 
studies: In the current meta-analysis, a total of 
28 studies with 24,008 study participants were 
included to identify risk factors of anemia 
among CKD patients. Regarding study design, 
most (75%) of the studies included were cross-
sectional. The number of participants per study 
ranged from 39 to 5,222. Risk factors of anemia 
patients with CKD were obtained from various 
areas across the globe. Twelve studies involved 
participants from Africa (13-15,38-46), nine 
from Asia (18,47-53), four from Europe (28,54-
56), and three from America (9,11,57).With 
respect to the tools used to assess anemia in 
CKD patients, eleven studies (11,12,15,38,43-
45,48,49,52,57) used the WHO definition, nine 
studies (13,14,42,46,47,51,53,55,56) used the 
Kidney Disease Outcome Quality Initiative, and 
three studies (28,39,41) did not specify the tool 
they used.The quality score of each primary 
study, based on the Newcastle-Ottawa quality 
score assessment, was moderate to high for all 
the 28 articles assessed (Table 1). 
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FACTORS ASSOCIATED WITH ANEMIA 
AMONG CKD PATIENTS 
 
Gender: According to our current meta-
analysis, females were 36% more likely to 
develop anemia in patients with CKD than male 
patients (AOR, 1.36, 95% CI 1.11, 1.67, I2 
=48.6%) (Figure 2). The evidence from Egger’s 
regression test shows that there was no 
publication bias (P = 0.203). 
 
Stage of CKD: The pooled effects of seven 
studies showed that stage 5 CKD patients 
were13 times more likely to develop anemia 
than patients with stage 1 CKD [AOR = 13.66; 
95% CI: 5.19, 35.92, I2 =81.2%], (Figure 3).The 
evidence from Egger’s regression test showed 
that there was publication bias (P = 0.005). 
             Age: According to the currentmeta-analysis, the 
pooled effects of four studies (14,15,46,49) 
indicated that those over 50 years of age  were 
62% more likely to develop anemia compared to 
those less than 50 years old, although this 
association was not statistically significant (OR: 
1.62 (95% CI (0.69, 3.79)). The result of the 
Egger’s regression test showed no evidence of 
publication bias (P = 0.385). 
 
Body mass index: The current meta-analysis 
showed that patients with BMI ≥30 kg/m2 were 
49% less likely to develop anemia compared 
with patients whose BMI was between 18.5 and 
25 kg/m2 [AOR = 0.51; 95% CI: 0.29, 0.91, I2 
=75%] (Figure 4). The evidence from Egger’s 
regression test shows that there was no 
publication bias (P = 0.181). 
 
Comorbidities: The present meta-analysis 
revealed that patients with comorbidities were 
nearly 3 times more likely to develop anemia 
than those with no evidence of comorbidities 
[AOR = 2.90; 95% CI: 1.68, 5.0, I2 = 86%] 
(Figure 5). The evidence from Egger’s test 






                                                                                                       
            Risk Factors for Anemia…                                                 Wondimeneh S.S. et al. 
 
 
DOI:  http://dx.doi.org/10.4314/ejhs.v30i5.23 
 
833 
Table 1: Baseline characteristics of the included studies 
 




The diagnosis of anemia  Risk factors Quality 
score 




Afshar R ., et al. [48] 2010 Iran, Asia 100 NKF-K/DOQI BUN, Hb concentration, creatinine 
clearance 
6 
Akinola OI., et al. [40] 2018 Nigeria, Africa 55 WHO definition  aging, female  gender,  history  of  
DM,  declining  eGFR 
6 
Akinsola A., et al. [41] 2000 Nigeria, Africa  39 Not Specified severity of the renal failure 6 
Bueno CS ., et al. [11] 2013 Brazil, South America  45 WHO definition  ferritin,creatinine,urea under 6 




Delestudio., et al. [55] 2014 Spain, Europe  504  NKF Stage of CKD 8 
Di Iorio B ., et al. [56] 2007 Italy, Europe  2,746 K-DOQI  Gender, years of dialysis, BMI, 
serum albumin, and calcium 
8 
Elgari MM ., et al. [38] 2019 Sudan, Africa  100 Not Specified erythropoietin and iron therapy 6 
Han JS., et al. [49] 2015 Korean, Asia  1,456 WHO definition  Albuminuria 8 
Haupt L ., et al. [43] 2016 South Africa, Africa  49 K-DOQI Iron therapy  6 
Juma A [44] 2012 Tanzania, Africa  100 WHO definition  EPO level 7 
Jungers PY., et al. [57] 2002 France, Europe  403 K-DOQI Epoetin therapy 
Creatinine clearance 
8 
Kaze FF., et al. [13] 2015 Cameroon, Africa  95 K-DOQI Erythropoietin treatment 
 
6 
Li Y., et al. [12] 2016 China, Asia 2,420 WHO definition  advancing CKD stage, iron therapy,  
chronicglomerulonephritis 
8 
Lau et al[18] 2015 Singapore, Asia  457 KDIGO  stage 5 CKD,  
hematological and respiratory 
disorders 
7 
Maïz HB ., et al. [45] 2002 Tunisian, Africa  304 WHO definition  History of dialysis  7 
McClellanW., et al.[9] 2004 United state, North America  5,222 <12mg/dl  EPO therapy 8 
Meremo AJ., et al. [46] 2017 Tanzania, Africa  792 WHO definition  blood loss, eGFR,serum creatinine 
level, and Urea level 
7 
Nalado AM., et al. [14] 2019 South Africa, Africa  397 K-DOQI CKD stage V, Diabetes  
Mellitus, ethnic disparity 
6 
Raji YR, et al. [47] 2020 Nigeria, Africa  314 K-DOQI Female gender 
severity of CKD 
6 
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Ryu S-R., et al. [50] 2017 Korean, Asia  2,198 WHO definition  CKD stages, body mass index 
(BMI), smoking, leukocyte 
count, serum albumin, iron 
markers, calcium, and 
phosphorus concentration 
8 
Salman M ., et al. [51] 2016 Malaysia, Asia  615 KDIGO advanced stages of CKD, iron 
therapy  
8 
Shaheen FA ., et al. [52] 2011 Saudi, Asia  250 K-DOQI Advanced stages of CKD, iron 
therapy  
7 
Stauffer ME., etal[39] 2014 United state, North America  1,691 NAAC and WHO Advanced stage of CKD 8 
Stirnadel-Farrant HA., et al. [28] 2018 England, Europe  266 Not Specified advanced CKD, diabetes mellitus, 
peripheral vascular disease 
7 
Suega K ., et al. [53] 2005 Indonesia,Asia  52 WHO definition  Low serum folic acid 6 




K-DOQI: Kidney Disease Outcome Quality Initiative; NKF:National Kidney Foundation;NAAC: National Anemia Action Council; WHO: World 
Health Organization;KDIGO: Kidney Disease: Improving Global Outcomes 
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Figure 2: The pooled effects of sex on anemia patients with CKD 
 
 
Figure 3:The pooled effects of stage of CKD on anemia  
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Figure 4: The pooled effect of body mass index on anemia patients with CKD 
 
Figure 5: The pooled effect of comorbidities on anemia patients with CKD 
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Proteinuria: The pooled effects of two studies 
(15,49) showed that those patients who had 3+ 
urine protein were 3.57 times more likely to 
develop anemia than patients who did not have 
proteinuria [AOR = 3.57; 95% CI: 1.03, 12.93, 
I2 =81.7%]. 
 
Hypocalcaemia: Patients with hypocalcaemia 
had four fold higher odds for anemia 
(AOR=3.61, 95%CI: 1.56–8.36, I2=88.3) 
compared with patients with normal serum 
calcium levels. The evidence from Egger’s test 
shows no significant proof of publication bias (P 
= 0.482). 
 
Iron therapy: According to the current meta-
analysis, the pooled effects of two studies 
(18,46) indicated that those receiving iron 
therapy were 41% less likely to develop anemia 
compared to those who had not taken iron 
therapy (AOR: 0.59, 95% CI 0.31, 0.99). The 
heterogeneity test (I2= 20.8%) showed no 




This study aimed to synthesize evidence on 
the risk factors of anemia in patients with CKD 
at a global level. Based on the pooled analysis of 
adjusted odd ratio of studies, being female, stage 
5 CKD, BMI≥30 kg/m2, comorbidity, 
proteinuria 3+, hypocalcaemia, and receiving 
iron therapy were associated with anemia of 
CKD. 
The current study revealed that female 
CKD patients were 36% more likely to develop 
anemia. This finding is supported by previous 
studies conducted in Korea (58), Australia(59), 
London (60), and New York (16).This would 
suggest that female patients had lower Hb 
concentrations than male patients, which likely 
explains why females had greater risk of 
developing anemia (9). Similarly, we found that 
those who had BMI ≥30 kg/m2 were 49% less 
likely to develop anemia of CKD compared to 
BMI<18.5 kg/m2. This finding was supported 
by other studies conducted in Korea (49); 
however, in contrast to a study from Australia 
(59).This variation might explain underweight 
may represent a malnourished state, which is 
closely related with chronic inflammation in 
CKD (49). 
The present study showed that CKD 
patients with pre-existing illnesses were nearly 
three times more likely to develop anemia, 
which mirrors results from studies in  Australia 
(59), London (60) and Malaysia (61).This 
finding suggests that any CKD patient who 
presents with comorbidities should be more 
closely monitored for anemia. Approprite 
management of comorbid illnesses may 
therefore reduce the odds of developing anemia.  
Those patients with advanced stage of CKD 
(stage 5) had a significant association with a 
anemia, which has been previously reported in 
studies conducted inAustralia (59), Korea (60), 
New York (16) and Florida (62).This association 
is likely explained by the deterioration of renal 
function being accompanied by a reduction in 
erythropoietin production by the kidneys, and 
the loss of erythropoietin results in decreased red 
blood cell production that increases the risk of 
anemia development (5,22,63). 
In the present review, proteinuria 3+ 
increased the risk of anemia by 57% compared 
with patients who do not have proteinuria. This 
finding is in agreement with a study conducted 
in Korea (58). Evidence further supports that 
low serum albumin due to protein malnutrition 
and/or inflammation is responsible for 
inadequate response to EPO treatment (64). In 
addition, it is necessary to investigate the 
interplay between proteinuria and the 
development of anemia in CKD. 
Those Patients with hypocalcaemia had a 
significant association with anemia of CKD. 
This result is related to the potential for high 
serum calcium to favor the control of anemia via 
inhibition of parathyroid hormone secretion, a 
factor which is considered responsible for EPO 
resistance in hemodialysis patients (65). 
We found that patients who have taken iron 
therapy were 41% less likely to develop anemia 
of CKD, which was supported by studies from 
Cleveland, USA (22) and China (12). In 
addition, a randomized control study showed 
beneficial erythropoietic effect of iron treatment 
in CKD 3–5 patients having ferritin even more 
than 100 ng/mL (66). 
This study has clinical implications in that 
the high magnitude of anemia in patients with 
CKD should guide healthcare professionals to 
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minimize the risk of anemia by providing 
guidance to the patient who could be detected in 
health checkups, give information about possible 
risk factors during routine patient care, and 
provide knowledge about potential risk of 
anemia. In addition, identifying associated risk 
factors may help healthcare professionals treat 
anemia patients with CKD during their clinical 
care. 
There are certain limitations to this review 
which must be acknowledged and may inform 
future research. First, we only used English 
language published articles Second, we did not 
pool all predictors of anemia in patients with 
CKD.   
In general, being female, stage 5 CKD, 
body mass index ≥ 30 kg/m2, comorbidity and 
hypocalcaemia were found to be significantly 
associated with anemia of chronic kidney 
disease.  Therefore, situation-based interventions 
and country context-specific preventive 
strategies should be developed to reduce the risk 
factors of anemia in this patient group.  In 
addition, this meta-analysis may help policy-
makers and program managers design evidence-
based interventions on preventing the occurrence 
of anemia with CKD patient populations. 
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